Naveris, a molecular diagnostics company, has partnered with large-scale medical and research center Mayo Clinic to launch the DART 2.0 clinical trial to assess its NavDx blood test. DART 2.0 builds on the results of a previous clinical trial, in which NavDx-detected molecular residual disease (MRD) was a significant risk factor for cancer recurrence in patients with head and neck cancer.
The DART 2.0 trial will evaluate the ability of NavDx, Naveris’ flagship blood test for tumor tissue modified viral (TTMV)-HPV DNA to improve treatment selection in patients with HPV-driven head and neck cancer. NavDx provides a non-invasive and precise method for monitoring molecular residual disease (MRD) and recurrence by analyzing tumor-derived viral DNA in patients' blood samples.
Naveris develops molecular diagnostics or blood tests that enable the earlier detection of viral-driven cancers. Its flagship product, NavDx, is a non-invasive test designed to monitor cancer recurrence based on viral DNA to enhance treatment selection in patients with HPV-driven head and neck cancer.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.